NCT00012298 · REGISTRY CONDITION SEARCH

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2018-08-09

Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Yttrium Y-90 Ibritumomab Tiuxetan (Y2B8) With and Without Filgrastim (G-CSF) and Interleukin-11 (IL-11) (Phase I)

→

outcome · POSTED

Toxicity of Single-dose Y2B8 Radioimmunotherapy With and Without the Use of Growth Factors (Phase I)

→

outcome · POSTED

Proportion of Patients Who Receive 2 Sequential Doses of Y2B8 Immunotherapy and Are Progression-free (Phase II)

→

outcome · POSTED

Association Between the Amounts of Tumor Radiation Indicated by the In2B8 Scan and Tumor Response (Phase I)

→

outcome · POSTED

Association Between In2B8 Scan and Positron Emission Tomography Scan Results (Phase I)

→

outcome · POSTED

Appearance of Tumor and Normal Organ Images on the Second In2B8 Scan (Phase I)

→

outcome · POSTED

Survival (Phase II)

→

outcome · POSTED

Time to Disease Progression (Phase II)

→

outcome · POSTED

Tumor Response Rate (Phase II)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically proven relapsed or refractory low-grade or follicular CD+ non-Hodgkin lymphoma, including 1 of the following: * Small lymphocytic lymphoma * Lymphoplasmacytoid lymphoma * Follicular center lymphoma (grades I, II, and III) * Extranodal marginal zone B-cell lymphoma * Nodal marginal zone B-cell lymphoma * Splenic marginal zone B-cell lymphoma (monocytoid B-cell lymphoma) * Less than 25% bone marrow involvement of cellular marrow with lymphoma by bilateral bone marrow aspirate and biopsy * ECOG performance status 0-2 * Bidimensionally measurable disease with at least 1 lesion \>= 2 cm in the greatest diameter * No prior myeloablative therapy with autologous or allogeneic bone marrow transplantation or peripheral blood stem cell support * No concurrent corticosteroid therapy, except prednisone (or equivalent) for adrenal failure or \< 20mg of prednisone daily * No prior external beam radiotherapy to \>25% of active bone marrow * More than 4 weeks since prior surgery other than diagnostic surgery * No other concurrent myelosuppressive antineoplastic agents * No prior radioimmunotherapy, including yttrium Y 90 ibritumomab tiuxetan or iodine I 131 monoclonal antibody tositumomab or Lym-1 * No CNS lymphoma * No myelodysplastic syndromes or marrow chromosomal changes suggesting myelodysplasia * No HIV or AIDS-related lymphoma * No pleural effusion or ascites with lymphoma cells * No active infection * No other serious non-malignant disease that would preclude study participation * No other active primary malignancy * No known human anti-mouse or human anti-chimeric antibody * No prior skin rash (e.g., Stevens-Johnsons syndrome or toxic epidermal necrolysis) from rituximab therapy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Absolute neutrophil count \>= 1,500/mm\^3 * Platelet count \>= 150,000/mm\^3 * Total lymphocyte count \< 5,000/mm\^3 for patients with small lymphocytic lymphoma * Bilirubin =\< 2 mg/dL * Creatinine =\< 2 mg/dL
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
intervention Names
Biological: rituximab
Biological: yttrium Y 90 ibritumomab tiuxetan
Biological: indium In 111 ibritumomab tiuxetan
Biological: oprelvekin
Biological: filgrastim
label
Treatment (radiolabeled monoclonal antibody therapy)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (radiolabeled monoclonal antibody therapy)
description
Given IV
name
rituximab
other Names
IDEC-C2B8
IDEC-C2B8 monoclonal antibody
Mabthera
MOAB IDEC-C2B8
Rituxan
type
BIOLOGICAL
arm Group Labels
Treatment (radiolabeled monoclonal antibody therapy)
description
Given IV
name
yttrium Y 90 ibritumomab tiuxetan
other Names
90Y ibritumomab tiuxetan
IDEC Y2B8
Y90 Zevalin
Y90-labeled ibritumomab tiuxetan
type
BIOLOGICAL
arm Group Labels
Treatment (radiolabeled monoclonal antibody therapy)
description
Given IV
name
indium In 111 ibritumomab tiuxetan
other Names
IDEC-In2B8
type
BIOLOGICAL
arm Group Labels
Treatment (radiolabeled monoclonal antibody therapy)
description
Given subcutaneously
name
oprelvekin
other Names
adipogenesis inhibitory factor
IL-11
interleukin 11
Neumega
type
BIOLOGICAL
arm Group Labels
Treatment (radiolabeled monoclonal antibody therapy)
description
Given subcutaneously
name
filgrastim
other Names
G-CSF
Neupogen
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 81
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
This study is a series of 3 single-arm phase-I trials designed to determine the maximum tolerated dose (MTD) of a 2-cycle combination regimen containing Rituxan + Y2B8 radioimmunotherapy with and without the use of G-CSF and IL-11. Trial 1 will determine the Y2B8 MTD in the combined regimen without growth factors. Trial 2 will evaluate the combined regimen with growth factors. Trial 3 starts IL-11 earlier (when platelet count drops below 150000) and reduces the dosing interval to twice weekly. \> Dose-limiting toxicity (DLT) is defined as an adverse event in the second cycle attributed to treatment and meeting the following criteria: Grade 4 ANC or platelet decrease for 14 days, or grade 3 for 28 days, or any other grade 3 Non-Heme event. \> If at any time 2 or more patients (of a maximum of 6) at any dose level experience DLT, then the MTD will be defined as the previous dose level during that trial. The number of patients with a DLT are reported here.
measure
Maximum Tolerated Dose (MTD) of Yttrium Y-90 Ibritumomab Tiuxetan (Y2B8) With and Without Filgrastim (G-CSF) and Interleukin-11 (IL-11) (Phase I)
time Frame
At 8 weeks
description
Evaluated using the Common Toxicity Criteria (CTC) version 2.0. This data is presented as the number of patients reporting grade 3 or higher, grade 4 or higher, or grade 5 adverse events regardless of event attribution.
measure
Toxicity of Single-dose Y2B8 Radioimmunotherapy With and Without the Use of Growth Factors (Phase I)
time Frame
Assessed up to week 24
description
Estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated.
measure
Proportion of Patients Who Receive 2 Sequential Doses of Y2B8 Immunotherapy and Are Progression-free (Phase II)
time Frame
At 3 years

secondary Outcomes

description
Assessed using a correlated logistic regression model and generalized estimating equations (GEE). Covariates such as dose level and use of prophylactic cytokines may also be included in this model. A Wilcoxon test will be used to assess the equality of the distributions of the continuous levels of predicted tumor radiation from the In2B8 scans by response.
measure
Association Between the Amounts of Tumor Radiation Indicated by the In2B8 Scan and Tumor Response (Phase I)
time Frame
At week 12
description
Explored using a contingency table and sensitivity and specificity will be calculated using 90% exact confidence intervals.
measure
Association Between In2B8 Scan and Positron Emission Tomography Scan Results (Phase I)
time Frame
At week 12
description
Calculated from the serial gamma camera images. Compared using a signed-rank-test. Scatter plots will be used to further explore relationships between these residence times and Bland- Altman methods can be used to assess the agreement between the first and second In2B8 scan residence times.
measure
Appearance of Tumor and Normal Organ Images on the Second In2B8 Scan (Phase I)
time Frame
At week 12
description
Estimated using the method of Kaplan-Meier.
measure
Survival (Phase II)
time Frame
From registration to death due to any cause, assessed up to 5 years
description
Estimated using the method of Kaplan-Meier.
measure
Time to Disease Progression (Phase II)
time Frame
From registration to the earliest date documentation of>disease progression, assessed up to 5 years
description
Calculated by the number of tumor responses divided by the total number of evaluable patients. An exact binomial confidence interval will be calculated.
measure
Tumor Response Rate (Phase II)
time Frame
Assessed up to 5 years

Full study description

brief Summary: Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.
detailed Description: PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) administered with rituximab with and without filgrastim (G-CSF) and interleukin-11 (IL-11) in patients with relapsed low-grade or follicular CD20+ non-Hodgkin's lymphoma. (Phase I) II. Determine the toxicity of this regimen in these patients. III. Determine the response rate in patients treated with this regimen. IV. Compare tumor and normal organ dosimetry with positron emission tomography and computerized tomography scans, subsequent tumor response, and normal organ toxicity by utilizing indium In 111 ibritumomab tiuxetan radioimmunoconjugate scans before each IDEC-90Y2B8 dose in these patients. (Phase I) V. Determine the immune response to this regimen, in terms of human anti-mouse and human anti-chimeric antibody formation, in these patients. (Phase I) VI. Determine whether G-CSF and IL-11 can ameliorate the effect of the MTD of IDEC-90Y2B8 on bone marrow function in these patients. (Phase I) VII. Determine progression-free survival at 3 years. (Phase II) OUTLINE: PHASE I: Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 (for radioimaging), and IDEC-90Y2B8 IV over 10 minutes on day 8. Treatment repeats 24-36 weeks later for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose (MTD) of IDEC-90Y2B8 is determined, patients also receive filgrastim (G-CSF) subcutaneously (SC) daily beginning when absolute neutrophil count is less than 1,500/mm3 and continuing until blood counts recover. Patients also receive interleukin-11 (IL-11) SC beginning when platelet count is less than 75,000/mm\^3 and continuing until blood counts recover. Patients undergo PBSC transplantation only if marrow recovery is inadequate. Cohorts of 3-6 patients receive escalating doses of IDEC-90Y2B8 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to determine the MTD of this radioimmunotherapy with the addition of the prophylactic cytokines, G-CSF and IL-11. PHASE II: Patients receive rituximab, indium In 111 ibritumomab tiuxetan, and IDEC-90Y2B8 IV as determined at the MTD in phase I. Treatment repeats 24-36 weeks later for a total of 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-889e1920b206117f1c2d
requested nct id
NCT00012298
primary nct id
NCT00012298
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
d278f25f194434be74bbb72f50ac71d4151a329e92abd798923ae2339002d8ca
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-889e1920b206117f1c2d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00012298
occurrences
context exact
NCT00012298
end
11
exact text
NCT00012298
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/454/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
a4afe40d14b1755d653c33cc96fdef49152debfc3307d27fdc8215e3197c5eab
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice